Research programme: neuromuscular disorders therapeutics - Rubedo Life Sciences
Latest Information Update: 21 Jan 2021
At a glance
- Originator Rubedo Life Sciences
- Class Antidementias; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Dementia; Fatigue; Sarcopenia